ATE437963T1 - In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase - Google Patents

In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase

Info

Publication number
ATE437963T1
ATE437963T1 AT04723215T AT04723215T ATE437963T1 AT E437963 T1 ATE437963 T1 AT E437963T1 AT 04723215 T AT04723215 T AT 04723215T AT 04723215 T AT04723215 T AT 04723215T AT E437963 T1 ATE437963 T1 AT E437963T1
Authority
AT
Austria
Prior art keywords
cell carcinoma
vitro method
transitional cell
bladder
cancer
Prior art date
Application number
AT04723215T
Other languages
English (en)
Inventor
Martinez Antonio Martinez
Buela Laureano Simon
Cruz Simon Santa
Jimenez Maria Saenz
Vila Miguel Molina
Sanchez-Vallejo Corina Junquera
Roman Jose Javier Gomez
Gonzalez Jorge Cuevas
Original Assignee
Progenika Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma Sa filed Critical Progenika Biopharma Sa
Application granted granted Critical
Publication of ATE437963T1 publication Critical patent/ATE437963T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04723215T 2003-03-26 2004-03-25 In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase ATE437963T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300708 2003-03-26
PCT/EP2004/003219 WO2004085676A1 (en) 2003-03-26 2004-03-25 In vitro method to detect bladder transitional cell carcinoma

Publications (1)

Publication Number Publication Date
ATE437963T1 true ATE437963T1 (de) 2009-08-15

Family

ID=33041266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723215T ATE437963T1 (de) 2003-03-26 2004-03-25 In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase

Country Status (7)

Country Link
US (1) US8124331B2 (de)
EP (1) EP1611252B1 (de)
AT (1) ATE437963T1 (de)
DE (1) DE602004022266D1 (de)
DK (1) DK1611252T3 (de)
ES (1) ES2330634T3 (de)
WO (1) WO2004085676A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US9089601B2 (en) 2006-07-10 2015-07-28 University Of Rochester Pre- and intra-operative imaging of bladder cancer
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2754163C (en) 2009-03-25 2019-04-09 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20140030259A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
EP2902489B9 (de) * 2012-09-27 2018-02-07 Chugai Seiyaku Kabushiki Kaisha Fgfr3-fusionsgen und darauf gerichteter pharmazeutischer wirkstoff
JP6766037B2 (ja) * 2014-09-26 2020-10-07 ヤンセン ファーマシューティカ エヌ.ベー. Fgfr阻害剤による治療に応答性であるがん患者を同定する際の、fgfr変異遺伝子パネルの使用
US11360092B2 (en) 2016-08-05 2022-06-14 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
BR112023002455A2 (pt) 2020-08-21 2023-03-28 Genzyme Corp Anticorpos fgfr3 e métodos de uso

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
DE60032910T3 (de) * 1999-05-05 2010-07-29 Institut Curie Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3
ATE440869T1 (de) * 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon

Also Published As

Publication number Publication date
DK1611252T3 (da) 2009-11-23
DE602004022266D1 (de) 2009-09-10
EP1611252B1 (de) 2009-07-29
US20070092878A1 (en) 2007-04-26
EP1611252A1 (de) 2006-01-04
US8124331B2 (en) 2012-02-28
ES2330634T3 (es) 2009-12-14
WO2004085676A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
Bellamri et al. Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib
Emslie et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial
Kottmann et al. Pharmacologic inhibition of lactate production prevents myofibroblast differentiation
Gould et al. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
EP3112476A3 (de) Verfahren, zusammensetzungen, verwendungen und kits für vitamin-d-mangel und verwandten erkrankungen
Liu et al. Ursodeoxycholic acid attenuates acute aortic dissection formation in angiotensin II-infused apolipoprotein E-deficient mice associated with reduced ROS and increased Nrf2 levels
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
DE69920940D1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE263371T1 (de) Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs
ATE437963T1 (de) In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
Padilla et al. Blood pressure regulation VIII: resistance vessel tone and implications for a pro-atherogenic conduit artery endothelial cell phenotype
Zhao et al. Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells
Margue et al. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
BRPI0507958A (pt) biomarcadores
Podkowa et al. A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties